- Home
- VRDN vs PRTA Comparison
VRDN vs PRTA Comparison
Compare VRDN & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRDN
- PRTA
- Stock Information
- Founded
- VRDN 2006
- PRTA 2012
- Country
- VRDN United States
- PRTA Ireland
- Employees
- VRDN N/A
- PRTA N/A
- Industry
- VRDN Medical Specialities
- PRTA Biotechnology: Pharmaceutical Preparations
- Sector
- VRDN Health Care
- PRTA Health Care
- Exchange
- VRDN Nasdaq
- PRTA Nasdaq
- Market Cap
- VRDN 1.0B
- PRTA 809.8M
- IPO Year
- VRDN N/A
- PRTA N/A
- Fundamental
- Price
- VRDN $14.16
- PRTA $4.70
- Analyst Decision
- VRDN Strong Buy
- PRTA Buy
- Analyst Count
- VRDN 12
- PRTA 9
- Target Price
- VRDN $38.50
- PRTA $27.67
- AVG Volume (30 Days)
- VRDN 838.2K
- PRTA 2.8M
- Earning Date
- VRDN 05-06-2025
- PRTA 05-08-2025
- Dividend Yield
- VRDN N/A
- PRTA N/A
- EPS Growth
- VRDN N/A
- PRTA N/A
- EPS
- VRDN N/A
- PRTA N/A
- Revenue
- VRDN $302,000.00
- PRTA $137,935,000.00
- Revenue This Year
- VRDN N/A
- PRTA N/A
- Revenue Next Year
- VRDN $21,976.14
- PRTA $122.59
- P/E Ratio
- VRDN N/A
- PRTA N/A
- Revenue Growth
- VRDN 4.86
- PRTA 54.55
- 52 Week Low
- VRDN $9.90
- PRTA $4.32
- 52 Week High
- VRDN $27.20
- PRTA $25.42
- Technical
- Relative Strength Index (RSI)
- VRDN 55.33
- PRTA 19.42
- Support Level
- VRDN $13.37
- PRTA $4.42
- Resistance Level
- VRDN $14.18
- PRTA $4.94
- Average True Range (ATR)
- VRDN 0.67
- PRTA 0.47
- MACD
- VRDN 0.12
- PRTA -0.13
- Stochastic Oscillator
- VRDN 71.43
- PRTA 7.12
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).
About PRTA Prothena Corporation plc
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).